April 25, 2019 5:59pm
Volume was still low, the IBB rose (+1.01%) with the range of the 23 upside being +0.32% (RGNX) to +3.86% (FATE) while the 18 downside ranged from -0.06% (VCEL) to -9.59% (MDXG)
Q1/19 results: BioMarin Pharmaceuticals (BMRN) net loss of - $56.47 M or -$0.32 per share while reaffirming FY19 revenue guidance up to $1.75 B with cash, equivalents and investments of $1.2 billion and increased gross profits (+$20.4 M) driven by increased sales/product revenues.
Pre-open indications: 6 HITs and 0 MISS
If you were part of RMi’s daily discourse, you would be reading about today’s aftermath and be ready for Friday’s prelude!
Members only. Please login.